tickerreport.com
Neutralwww.tickerreport.com ·
cardiff oncology nasdaqcrdf issues earnings results
TAX_DISEASE_OVERWEIGHTWB_1406_DISEASESWB_1435_OBESITYWB_621_HEALTH_NUTRITION_AND_POPULATION
Topic context
This topic has been covered 311756 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEarnings miss for a clinical-stage biotech company; no direct commercial mechanism beyond stock price reaction. No product revenue, supply chain, or scarcity impact. The company is pre-commercial, so the earnings miss does not affect any product/commodity market.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Cardiff Oncology (NASDAQ: CRDF) reported EPS of ($0.18), missing estimates of ($0.13) by $0.05.
- Revenue was $0.04 million, below expected $0.09 million.
- Negative net margin of 7,733.22%.
- Shares increased by $0.04 to $1.73, market cap $118.28 million.
- Consensus rating 'Moderate Buy' with price target $10.10.
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
xponential xpof q1 2026 earnings 221145866
finance.yahoo.com
dxp dxpe q1 2026 earnings 215803136
economictimes.indiatimes.com
missiles over dubai rattle the gulfs billion dollar money machine dubai property uae deal ipo market
finance.yahoo.com